Welcome to our dedicated page for Allogene Therapeutics SEC filings (Ticker: ALLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC documents for a clinical-stage biotech are rarely light reading. Allogene Therapeutics’ 10-K blends immunology, CRISPR engineering, and complex revenue-recognition rules, while Form 4s can spike around trial milestones. If you have ever searched for “Allogene Therapeutics insider trading Form 4 transactions” or wondered how to extract cash-burn insights from a dense quarterly report, you know the challenge.
Stock Titan solves that problem. Our platform delivers AI-powered summaries that turn ALLO’s disclosures into plain English. Open the “Allogene Therapeutics quarterly earnings report 10-Q filing” and our engine flags R&D spend, enrollment updates, and liquidity runway in seconds. Need real-time alerts? We stream “Allogene Therapeutics Form 4 insider transactions real-time” so you can see executive stock moves the moment they hit EDGAR. Whether you are “understanding Allogene Therapeutics SEC documents with AI” for pipeline analysis or seeking an “Allogene Therapeutics earnings report filing analysis” to gauge dilution risk, every key point is surfaced automatically.
Our coverage spans every form: an “Allogene Therapeutics annual report 10-K simplified” to spotlight Dagger® manufacturing scale; an “Allogene Therapeutics proxy statement executive compensation” to reveal incentives linked to Phase 2 data; even an “Allogene Therapeutics 8-K material events explained” when the company announces FDA feedback or secondary offerings. Professional investors use these insights to monitor “Allogene Therapeutics executive stock transactions Form 4,” compare trial costs across quarters, and track strategic collaborations with ease. No more hunting through hundreds of pages—our AI delivers what matters, right when you need it.
Allogene Therapeutics reported continued operating losses while preserving a multi-quarter cash runway as it refocuses clinical priorities. The company recorded a net loss of $50.9 million for the quarter and $110.7 million year-to-date, driven by research and development and general and administrative expenses, although total operating expenses declined versus prior-year periods. Cash, cash equivalents and investments totaled $302.6 million as of June 30, 2025, and management expects funding into the second half of 2027. The company completed a ~28% workforce reduction, recording related severance and impairment charges, and recognized impairment on a to-be-sublet leased facility and certain equipment.
Clinical updates include RMAT designation and positive signal durability for ALLO-316, IND clearance and trial initiation for ALLO-329 (RESOLUTION), and a consequential change in the ALPHA3 trial lymphodepletion approach: the FCA arm was closed after a Grade 5 adverse event attributed to ALLO-647 and standard fludarabine/cyclophosphamide (FC) was selected as the lymphodepletion regimen. The company received $9.2 million under an amended CIRM award recorded as a liability.
The Schedule 13G/A discloses that Dr. Arie Belldegrun beneficially owns 12,605,894 shares of Allogene Therapeutics common stock, representing 5.7% of the class based on 218,730,809 shares outstanding. The reported holdings include 3,243,004 shares issuable within 60 days upon exercise of stock options and equity held through related entities: Bellco Legacy IV LLC (4,710,120), Bellco Legacy LLC (539,867), Vida Ventures LLC (1,798,163), Vida Ventures III, L.P. (1,720,172) and Vida Ventures III-A, L.P. (3,965).
Dr. Belldegrun disclaims beneficial ownership of the shares held by the Vida entities except to the extent of any pecuniary interest. The filing reports both sole and shared voting and dispositive powers for the aggregate position as set forth on the cover pages.
Allogene Therapeutics' Schedule 13G/A shows that David D. Chang, M.D., Ph.D., and related family trusts report combined beneficial ownership of 11,136,728 shares of common stock, representing 5.0% of the class. The filing states that this total includes 5,413,414 shares issuable upon exercise of options exercisable within 60 days, and breaks out voting and dispositive power as 8,223,532 shares sole and 2,913,196 shares shared. Separate trusts—the Chang 2006 Family Trust, JEC 2019 Trust and RTC 2019 Trust—report holdings of 1,201,108, 856,044 and 856,044 shares respectively, representing 0.5% and two 0.4% stakes. The percentage is calculated using 218,730,809 shares outstanding as disclosed by the issuer.
Insider Trading Alert: Allogene Therapeutics (ALLO) Director Vicki L. Sato received a significant stock option grant on June 18, 2025. The transaction details reveal:
- Granted 144,400 stock options to purchase common stock
- Exercise price set at $1.29 per share
- Options expire on June 18, 2035
- Vesting schedule: Equal monthly installments over 12 months
This Form 4 filing indicates a standard director compensation package through equity incentives. The relatively low exercise price and extended 10-year expiration term suggest a long-term alignment with shareholder interests. The monthly vesting schedule encourages continued service on the board. The transaction was executed directly, with no indirect ownership reported.
Allogene Therapeutics (ALLO) director Deborah M. Messemer received a significant equity grant on June 18, 2025. The insider was awarded 95,400 Restricted Stock Units (RSUs) with the following key terms:
- RSUs will vest in two equal semi-annual installments over one year from grant date
- Each RSU represents a right to receive one share of common stock
- Grant price was $0, as typical for RSU awards
- Director elected to defer receipt of shares until either:
- 30 days after Board separation
- Company change in control
This Form 4 filing represents standard non-employee director compensation and demonstrates continued alignment between board member and shareholder interests through equity-based compensation.
Franz B. Humer, Director at Allogene Therapeutics (ALLO), received a grant of 95,400 Restricted Stock Units (RSUs) on June 18, 2025. The RSUs represent the right to receive an equivalent number of common stock shares.
Key terms of the RSU grant:
- Vesting Schedule: Equal semi-annual installments over one year from grant date
- Exercise Price: $0
- Special Deferral: Humer elected to defer receipt of shares until either:
- 30 days after Board separation, or
- Company change in control
This Form 4 filing was submitted by Earl Douglas (Attorney-in-fact) on June 20, 2025, reporting the transaction under Section 16(a) of the Securities Exchange Act. The grant appears to be part of the company's Non-Employee Director Compensation Policy.
Elizabeth A. Barrett, Director of Allogene Therapeutics (ALLO), received a significant equity grant on June 18, 2025. The transaction involved the acquisition of 95,400 Restricted Stock Units (RSUs) with a $0 exercise price.
Key terms of the RSU grant:
- Vesting occurs in two equal semi-annual installments over one year from grant date
- Each RSU converts to one share of common stock
- Barrett elected to defer receipt of shares until either:
- 30 days after Board separation
- Company change in control
The grant represents part of the company's Non-Employee Director Compensation Policy. The filing was executed by Earl Douglas as Attorney-in-Fact on June 20, 2025.
FAQ
What is the current stock price of Allogene Therapeutics (ALLO)?
What is the market cap of Allogene Therapeutics (ALLO)?
